Daclatasvir

Janessa M. Smith, PharmD, BCPS
Daclatasvir is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or .

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Treatment of chronic hepatitis C virus (HCV) genotype 1 or 3 infection, in combination with sofosbuvir (SOF).
    • Daclatasvir is indicated for treatment of HIV/HCV co-infected patients, in patients with compensated Child-Pugh Class A cirrhosis, decompensated Child-Pugh B or C cirrhosis and in patients that develop recurrent HCV post-transplant.

NON-FDA APPROVED USES

Treatment of HCV genotypes 2, 4.

-- To view the remaining sections of this topic, please or --

INDICATIONS

FDA

  • Treatment of chronic hepatitis C virus (HCV) genotype 1 or 3 infection, in combination with sofosbuvir (SOF).
    • Daclatasvir is indicated for treatment of HIV/HCV co-infected patients, in patients with compensated Child-Pugh Class A cirrhosis, decompensated Child-Pugh B or C cirrhosis and in patients that develop recurrent HCV post-transplant.

NON-FDA APPROVED USES

Treatment of HCV genotypes 2, 4.

There's more to see -- the rest of this entry is available only to subscribers.

Last updated: August 1, 2016